Novartis expects to resume shipping drugs made at its Nebraska, US plant by the end of the year and is on track to fix other quality issues at Sandoz sites hits with 483s in 2011.
Novartis aims to focus on the development of specialty medicines in a new long-term strategy to boost profitability in a rapidly changing healthcare environment.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Vasella stepping down as CEO of Novartis and appointments at Shionogi Pharma and Antares Pharma.
Novartis intends to acquire the remaining 75 per cent of Alcon for $39.3bn (€27.3bn), adding to the shares it bought in April 2008 and giving the big pharma control of the ophthalmic specialist.
Novartis is investing $250m (€170m) to construct a facility in China focused on research, development and manufacture of APIs and has earmarked a further $1bn to expand its R&D activities in the country.
Industry response to the H1N1 pandemic suggests that cell culture vaccine production is about to come of age with two firms that use the technique, Novartis and Baxter, claiming it will cut development and manufacturing timelines by months.
Late last week the US Department of Health and Human Services (HHS) awarded Novartis a $490m contract to continue work on its cell-culture influenza vaccine plant in Holly Springs, North Carolina, US. in-PharmaTechnologist spoke with Novartis spokesman...
Swiss-based Novartis has acquired a 25 per cent stake in Alcon, a
US-based company specializing in ophthalmics, which ranks among the
fastest-growing therapeutic sectors in pharmaceuticals.
Novartis has lent impetus to the growing trend towards
philanthropic R&D in the pharmaceutical industry by opening a
new research institute in Siena, Italy "with a non-profit
mission to exclusively focus on the development...
Novartis has been given a warning by US regulators detailing
significant failures in its investigation into tracking down the
source of contamination in some of its vaccines.
Novartis has been keen to shout about data published this week in
the Journal of the American Medical Association (JAMA)
that backs up claims that it has developed the first vaccine to
protect infants against the most common meningitis...
Swiss pharma Novartis today announced the largest manufacturing investment in its history, revealing plans for a $700m (€486.5m) biotech facility to be built alongside its new solid dose plant in the low cost, high quality biopharma hub of Singapore.
Novartis has hooked up with the Massachusetts Institute of
Technology (MIT) to fund a project aimed at 'revolutionising'
pharmaceutical manufacturing and doing away with traditional
batch-based production techniques.
Novartis and Bayer Schering Pharma have finally settled their
disputes over multiple sclerosis (MS) drug Betaseron (interferon
beta-1b), with an agreement outlined in March now complete.
Novartis is aiming to hunt down its rivals through a pipeline of
truly innovative drugs, measured by increasing numbers of New
Molecular Entities (NMEs) in development.
Novartis is to pull millions of planned investment dollars out of
India in reaction to intellectual property (IP) fears. The decision
may leave China as the cat that got the cream.
Novartis' has received US approval for its single-tablet
combination of the world's two most popular hypertension drugs,
taking advantage of rival patent expiries and shoring up its
portfolio.
Novartis and Bayer Schering Pharma have come to an agreement
regarding the production of multiple sclerosis (MS) drug Betaseron
(interferon beta-1b), with Novartis planning to bring out its own
version in 2009 and Bayer paying around...
After a ruthless battle between US states, Novartis has selected
Holly Springs in North Carolina for its vaccine manufacturing plant
which will use novel cell culture technology to dramatically speed
up production - the first facility...
Maryland is no longer in the running for a $500m (€392m) vaccine
manufacturing plant Novartis is seeking to build in the US, as
speculation about which state will host America's first cell
culture-derived influenza vaccine plant...
Looking to establish itself in Eastern Europe, French drug maker
Sanofi-Aventis has bought a 24.9 per cent stake in Czech generic
drug firm Zentiva for $514.7m (€430m).
Following hot on the heels of the GSK's expansion of its vaccine
division, Novartis is seeking to take control of vaccine maker
Chiron by buying the remaining shares it does not already own in
the US firm for $4.5bn (£2.5bn).
The future for Novartis' experimental cancer drug looked grim after
an ongoing clinical trial suggested that it was unlikely to boost
survival rates of patients with colon cancer. This is the second
setback for the drug this...
Shares in German generic drugmaker Stada rose last Friday after
rumours resurfaced that Israeli company Teva Pharmaceutical
Industries was gearing up to launch a €2 billion bid for the
company.
Swiss drugmaker Novartis has started construction of a $180 million
tabletting facility in Singapore, providing further evidence of the
emergence of the island state as a pharmaceutical hub.
Singapore's pharmaceutical output is likely to be flat this year, a
casualty of increasing pressure from generic drug firms. The
prediction, made by a Singapore official comes after the country
experienced a 40 per cent growth...
Novartis, the Swiss pharmaceutical giant has acquired two companies
as it aims to expand its generics drug portfolio and increase its
presence in the generics sector. The strategic move is expected to
make Novartis the world's...
The consolidation of the generic drugs industry continues, with
Novartis' unit Sandoz merging with two companies that will bring it
back into the number one position in the sector.
Figures released by the Association of the British Pharmaceutical
Industry (ABPI) has revealed that the level of intimidation posed
by animal extremists reaches as far as the suppliers who do
business with companies involved with...
A report out today cites Novartis' pipeline of drugs to continue
its reputation of producing quality pharmaceuticals, with
treatments for cancer, age-related macular degeneration and
hypertension expected to appear within the...
Inpharmatica has announced a discovery collaboration with Novartis
Institutes for Biomedical Research which is to focus on identifying
protein targets for Novartis' drug discovery projects.
Novartis has paid a US drug delivery company $10 million for an
option to an oral formulation of an injectable drug used to treat
osteoporosis that is currently the subject of litigation with Eli
Lilly.
The cumulative effect of patients failing to adhere to their
treatment regimens is costing the pharmaceutical industry in excess
of $30 billion a year, says a new report from Datamonitor which
proffers some solutions to the problem.
Novartis generics subsidiary Sandoz has continued its expansion
with the purchase of Canadian generic drugmaker Sabex Holdings for
$565 million (€459m) in cash, bringing in a new range of injectable
products.
Signalling its continued commitment to the emerging economies of
the recently expanded European Union, Switzerland's Novartis has
unveiled a €70 million overall investment in a new generics
production and logistics facility in...
Alex Matter is to direct the Novartis Institute for Tropical
Diseases (NITD) in Singapore after his retirement as Novartis
oncology chief later ths month.
